Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in refractory diabetes mellitus with insulin resistance
NCT04018365Phase 3Unknown
- Sponsor
- Kobe University
- Start
- Sep 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in Type A insulin resistance syndrome (TAIRS), insulin resistance syndrome type B (TBIRS), lipoatrophic diabetes mellitus, insulin resistance syndrome, sponsored by Kobe University. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
Type A insulin resistance syndrome (TAIRS)insulin resistance syndrome type B (TBIRS)lipoatrophic diabetes mellitusinsulin resistance syndrome
Beyond the preview
Go deeper on NCT04018365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018365.